文献速递神经核医学

长新冠持续症状患者脑代谢持续受损:一项为期九个月的随访[18F]FDG-PET研究

Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-12

回顾性分析56例长新冠患者急性感染后平均7个月(PET1)和16个月(PET2)的两次脑[18F]FDG-PET,并与51名健康受试者比较。两次显像均显示边缘区、脑桥和小脑低代谢,PET1与PET2间仅脑桥和小脑在较宽松未校正阈值下分别改善8.4%和5.2%,ROI分析未显示显著变化。结论为持续症状的长新冠患者存在持久脑代谢缺陷,但无进行性恶化。

要点

  • 长新冠持续症状患者在感染后约7个月和16个月两次PET均显示边缘区、脑桥和小脑低代谢。
  • PET1与PET2间仅脑桥和小脑在较宽松未校正阈值下分别改善8.4%和5.2%,ROI分析无显著变化。
  • 结论为脑代谢缺陷持久存在但无进行性恶化。

核心结论

  • 持续症状的长新冠患者存在持久脑代谢缺陷,但无进行性恶化。

研究设计与样本

  • 回顾性分析56例长新冠成人患者,在本院于2020年5月至2022年10月间接受两次脑[18F]FDG-PET,并与51名健康受试者比较。
  • PET1于急性新冠感染后平均7个月(范围3-17)进行,PET2于急性感染后16个月(范围8-32)进行,因持续严重或致残症状无显著临床恢复而复查。

主要发现

  • PET1和PET2均显示与既往文献报道一致的基于体素的低代谢。
  • PET1与PET2组间分析显示脑桥和小脑轻微改善(分别8.4%和5.2%),仅在较宽松未校正p阈值下显著;脑桥改善与PET1-PET2间隔相关(r=0.21,p<0.05)。
  • PET1识别的14,068个低代谢体素中,6,503个在PET2仍低代谢(46%);PET2识别的7,732个低代谢体素中,6,094个在PET1也低代谢(78%)。
  • ROI解剖分析证实PET1和PET2均存在累及边缘区、脑桥和小脑的脑低代谢,PET1与PET2间无显著变化。

关键数值与推荐

  • 体素分析采用p-voxel<0.001未校正、p-cluster<0.05 FWE校正;PET1与PET2比较另采用较宽松阈值p-voxel<0.005未校正、p-cluster<0.05未校正。
  • ROI半定量解剖分析采用p<0.05校正。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A hypometabolic profile involving the limbic areas, brainstem and cerebellum has been identified in long COVID patients using [18F]fluorodeoxyglucose (FDG)-PET. This study was conducted to evaluate possible recovery of brain metabolism during the follow-up of patients with prolonged symptoms. METHODS: Fifty-six adults with long COVID who underwent two brain [18F]FDG-PET scans in our department between May 2020 and October 2022 were retrospectively analysed, and compared to 51 healthy subjects. On average, PET1 was performed 7 months (range 3-17) after acute COVID-19 infection, and PET2 was performed 16 months (range 8-32) after acute infection, because of persistent severe or disabling symptoms, without significant clinical recovery. Whole-brain voxel-based analysis compared PET1 and PET2 from long COVID patients to scans from healthy subjects (p-voxel < 0.001 uncorrected, p-cluster < 0.05 FWE-corrected) and PET1 to PET2 (with the same threshold, and secondarily with a less constrained threshold of p-voxel < 0.005 uncorrected, p-cluster < 0.05 uncorrected). Additionally, a region-of-interest (ROI) semiquantitative anatomical approach was performed for the same comparisons (p < 0.05, corrected). RESULTS: PET1 and PET2 revealed voxel-based hypometabolisms consistent with the previously reported profile in the literature. This between-group analysis comparing PET1 and PET2 showed minor improvements in the pons and cerebellum (8.4 and 5.2%, respectively, only significant under the less constrained uncorrected p-threshold); for the pons, this improvement was correlated with the PET1-PET2 interval (r = 0.21, p < 0.05). Of the 14,068 hypometabolic voxels identified on PET1, 6,503 were also hypometabolic on PET2 (46%). Of the 7,732 hypometabolic voxels identified on PET2, 6,094 were also hypometabolic on PET1 (78%). The anatomical ROI analysis confirmed the brain hypometabolism involving limbic region, the pons and cerebellum at PET1 and PET2, without significant changes between PET1 and PET2. CONCLUSION: Subjects with persistent symptoms of long COVID exhibit durable deficits in brain metabolism, without progressive worsening.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Horowitz T, Dudouet P, Campion JY, et al. Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38862619. doi:10.1007/s00259-024-06775-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。